Compare Agilent Technologies Inc (A) vs Docusign Inc (DOCU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Docusign Inc — how do they compare? Agilent Technologies Inc trades at $128.76 (market cap $37.04B), while Docusign Inc trades at $47.11 (market cap $9.02B). The key difference: Agilent Technologies Inc is far larger — about 4.1× Docusign Inc's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Docusign Inc pays none. Which is the better fit depends on your goals.
| A | DOCU | |
|---|---|---|
Market Cap | $37.04B | $9.02B |
Sector | Health | Technology |
52-Week High | $157.20 | $85.01 |
52-Week Low | $110.24 | $41.75 |
Enterprise Value | $38.59B | $8.39B |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
DOCU trades at $47.23, up 3.19% with a bullish technical signal. Recent earnings consistently beat expectations, with Q1 2026 EPS of $1.09 exceeding estimates. Revenue growth remains steady, reaching $2.98B in 2025, while profitability improved significantly with a net income margin of 35.87%. The company's partnerships with Perplexity and Slack highlight ongoing innovation in agreement management workflows, supporting future growth prospects amid positive analyst sentiment.
The outlook for DOCU is cautiously optimistic, with a consensus price target of $55.40 suggesting 17% upside. Key opportunities include expanding AI integration and enterprise adoption, but risks involve competitive pressures and reliance on subscription revenue stability. Valuation metrics like a P/E of 30.45 require sustained earnings growth to justify current levels, making execution critical for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →
